Child pages
  • Proteogenomic analysis of chemo-refractory high grade serous ovarian cancer (PTRC-HGSOC)

Versions Compared


  • This line was added.
  • This line was removed.
  • Formatting was changed.




In our study, we have generated proteomic and genomic (RNA sequencing and whole genome sequencing) profiles from high grade serous ovarian cancer (HGSOC) tumor biopsies. All biospecimens are formalin-fixed, parrafin-embedded (FFPE) tissues and annotated for patient sensitivity to platinum chemotherapy (refractory or sensitive). For all 174 tumors that were analyzed, we have H&E-stained and imaged the first and last sections (“bookend”) cut from each FFPE block to allow study of tumor pathology. These H&E pathology images are uploaded in this dataset. The 174 tumors represented 158 unique patients (imaging was performed on two FFPE blocks for a small subset of patients where additional tumor mass was required for proteomic analysis). The bookend FFPE slides were cut at 4 μm thickness using a microtome and mounted on glass slides (Leica Biosystems Cat# 3800040) for H&E staining. Digital images of the H&E slides were recorded using a ScanScope AT Slide Scanner (Leica Aperio Technologies, Vista, CA, USA) under 20X objective magnification (0.5 μm resolution). Images were analyzed by HALO Image Analysis Platform software (Indicta Labs, Albuquerque, New Mexico, USA).

The following clinical data are also provided for these subjects: 

  • Image file name (combination of Image Name and Image ID) and corresponding sample IDs
  • Chemotherapy response status: (sensitive/refractory; refractory is defined in our study as clinical ovarian cancer that progresses while on platinum-based therapy or within 4 weeks)
  • neo-adjuvant treatment (yes/no)
  • Tumor location
  • Tumor grade, stage, substage
  • Patient age
  • Patient ethnicity
  • Patient race
  • Age of sample

The goals of the study were to understand mechanisms of platinum resistance in epithelial ovarian cancers (EOCs) in order to: i) predict EOCs that will respond to DNA-damaging platinum therapy, and ii) identify potential new drug targets in resistant disease to point to desperately needed new therapeutic approaches. The ability to predict platinum-resistant/refractory disease would be clinically impactful by enabling the immediate triage of patients with refractory disease to clinical trials of experimental therapies, avoiding use of ineffective standard of care chemotherapy and helping to identify novel treatments. In this study, we generated proteomic and genomic (RNA sequencing and whole genome sequencing) profiling datasets and H&E images from high grade serous ovarian cancer (HGSOC) tumor biopsies representing platinum-sensitive and platinum-refractory disease.